GS vs JNJ: Which Is the Better Buy?
Side-by-side comparison of The Goldman Sachs Group, Inc. and Johnson & Johnson — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-04-11.
The Goldman Sachs Group, Inc. · Financial Services
$907.80
-3.1% upside to fair value
Low Conviction
Grade C+
VS
Johnson & Johnson · Healthcare
$238.46
-11.8% upside to fair value
Med Conviction
Grade C+
QuantHub Verdict
GS has more upside to fair value
(-3.1%).
GS trades at a lower forward P/E
(15.6x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
GS |
JNJ |
| Current Price |
$907.80 |
$238.46 |
| Fair Value Estimate |
$880.00 |
$210.28 |
| Upside to Fair Value |
-3.1%
|
-11.8%
|
| Market Cap |
$269.4B |
$574.7B |
| Forward P/E |
15.6x
|
20.2x
|
| EV / EBITDA |
29.7x
|
13.3x
|
| Price / Sales |
2.1x
|
6.2x
|
| Price / FCF |
—
|
29.4x
|
| Revenue Growth YoY |
+9.0%
|
+6.1%
|
| Gross Margin |
47.5%
|
72.8%
|
| Operating Margin |
17.5%
|
27.2%
|
| Return on Equity |
13.8%
|
32.87%
|
| Dividend Yield |
1.71% |
2.18% |
| FCF Yield |
—
|
3.4%
|
| Analyst Consensus |
Buy
|
Moderate Buy
|
Investment Thesis
Goldman Sachs remains the premier global investment bank with dominant franchises in M&A advisory, equities trading, and asset management. FY2025 delivered $58.3B net revenues, 15% ROE, and $51.32 diluted EPS, powered by record equities trading and a resurgent IB pipeline. The stock has pulled back 8% from January highs near $985 but still trades at 2.27x book value, well above the 5-year median …
Johnson & Johnson is a high-quality healthcare conglomerate focused exclusively on Innovative Medicine and MedTech following the Kenvue spin-off. The company delivered $94.2B in FY2025 revenue with 6% operational growth, generated $19.7B in free cash flow, and guided for $99.5-100.5B in 2026 operational sales (above consensus). However, at $238 the stock trades at a P/S of 6.15x, well above the 5…
Accumulation Zones
| Metric |
GS |
JNJ |
| Zone Low |
$600.00 |
$157.71 |
| Zone High |
$680.00 |
$178.74 |
| In Buy Zone? |
No
|
No
|